Cat and dog gastrointestinal inflammation alleviator containing plant extract and application thereof

Abstract

The invention discloses a cat and dog gastrointestinal inflammation alleviator containing plant extracts and application of the cat and dog gastrointestinal inflammation alleviator, and relates to the field of pet health. The alleviator is prepared by compounding a plant extract component, a micro-ecological component, a functional auxiliary component and a carrier raw material, plant active components are purified by adopting an ultrasonic-assisted ethanol gradient elution combined membrane separation technology, and the problem of antagonism of a plant extract and probiotics is solved through microcapsule embedding and step-by-step compounding. The sustained-release preparation is prepared by combining sustained-release preparation forming and palatability optimization technologies. The traditional Chinese medicine composition can synergistically achieve the effects of resisting inflammation, repairing gastrointestinal mucosa, regulating intestinal flora and quickly stopping diarrhea, is suitable for preventing and treating acute and chronic enterogastritis of cats and dogs, and is good in palatability, high in stability, free of obvious toxic and side effects and convenient to administrate.

Description

Technical Field

[0001] This invention relates to the field of pet health products technology, specifically to a cat and dog gastrointestinal inflammation reliever containing plant extracts and its application. Background Technology

[0002] With the increasing sophistication of pet care, the incidence of acute and chronic gastroenteritis in cats and dogs is rising year by year, causing symptoms such as vomiting, diarrhea, and loss of appetite, seriously affecting pets' health. Currently, most gastrointestinal relief products on the market are based on single probiotic preparations or chemical antidiarrheal drugs, which have problems such as low survival rate of probiotics, weak resistance to gastrointestinal fluids, and short duration of action; while chemical products are fast-acting, they can easily disrupt the balance of intestinal flora in pets, and long-term use poses a risk of side effects.

[0003] Plant extracts are gaining attention due to their mild and safe properties. Extracts such as licorice and astragalus have the potential to regulate intestinal function, but traditional extraction processes suffer from drawbacks such as low purity of active ingredients and poor extraction efficiency. At the same time, existing products generally lack targeted sustained-release design, making it difficult for active ingredients to be released in the intestines, and their poor palatability leads to low pet compliance.

[0004] Therefore, developing a cat and dog gastrointestinal inflammation relief agent that combines the synergistic effects of plant extracts and probiotics, is resistant to gastrointestinal fluids, has targeted sustained release, and is highly palatable has become an urgent technical problem to be solved in the current pet health product field. Summary of the Invention

[0005] To address the problems existing in the aforementioned background technology, this invention proposes an application of a cat and dog gastrointestinal inflammation relief agent containing plant extracts. This relief agent utilizes the synergistic effect of plant extracts and probiotics, combined with microencapsulation technology to enhance the probiotics' resistance to gastrointestinal fluids and survival rate. It employs composite sustained-release materials to achieve targeted release of active ingredients into the intestines, and incorporates various natural flavoring agents to improve palatability. It also possesses the advantages of being mild and safe, having a long-lasting effect, and having no side effects, thus meeting the diverse needs for the prevention and treatment of acute and chronic gastroenteritis in cats and dogs.

[0006] To achieve the above objectives, the present invention adopts the following technical solution: A gastrointestinal inflammation reliever for cats and dogs containing plant extracts, said reliever being prepared from the following raw materials in parts by weight: The composition includes 3-8 parts plant extract, 2-6 parts microecological components, 4-10 parts functional auxiliary components, 3-8 parts composite encapsulation material, 0.5-2 parts flavoring agent, 0.05-0.2 parts natural antioxidant, and 65.8-87.45 parts carrier raw material. The plant extract components include 0.8-2 parts of licorice extract, 0.6-1.8 parts of astragalus extract, 0.5-1.5 parts of poria cocos extract, and 0.5-1.2 parts of yam extract; the microecological components include 0.5-1.5 parts of probiotics and 1-3 parts of brewer's yeast powder, wherein the probiotics contain 0.2-0.6 parts of bifidobacteria and 0.3-0.9 parts of lactic acid bacteria; the functional auxiliary components include 1.5-4 parts of prebiotics and 2-4 parts of montmorillonite powder, wherein the prebiotics contain 0.5-1.5 parts of xylooligosaccharides, 0.4-1.2 parts of fructooligosaccharides, and 0.3-0.8 parts of galactooligosaccharides; the composite encapsulation material includes 1-4 parts of maltodextrin, 0.5-3 parts of gum arabic, and 0.3-2 parts of trehalose; the carrier raw material includes 50-75 parts of corn starch, 5-12 parts of lactose, and 1-3 parts of sodium carboxymethyl cellulose.

[0007] Optionally, the probiotics are microencapsulated compound probiotics, the wall thickness of the microcapsules is 1-5 μm, and the survival rate of the probiotics in the formulation is 90%-95% in simulated gastrointestinal fluid for 2 hours.

[0008] Optionally, the reliever is a sustained-release granule with an in vitro release rate of 20%-30% in gastric juice after 2 hours and 70%-90% in intestinal juice after 8 hours.

[0009] Optionally, the preparation method of the aforementioned cat and dog gastrointestinal inflammation relief agent containing plant extracts includes the following specific preparation steps: S1. Using ultrasound-assisted ethanol gradient elution combined with membrane separation purification technology, licorice, astragalus, poria cocos and yam were extracted and purified separately. The extraction conditions were: ultrasonic power 150-300 W, extraction temperature 40-60℃, extraction time 30-90 min, ethanol gradient concentration 30%-80%, and ultrafiltration membrane with a molecular weight cutoff of 5000-10000 Da was used for membrane separation to obtain plant extracts with a core active ingredient purity of 85%-98%. S2. A composite encapsulation material is prepared by mixing maltodextrin, gum arabic, and trehalose in a mass ratio of 1-3:1-2:0.5-1. This material is used to microencapsulate Bifidobacteria and Lactobacillus, ensuring a probiotic survival rate of 95%-99% in the formulation. S3. Mix the plant extract components, functional auxiliary components, and carrier raw materials evenly, dry them to a moisture content of 2%-5%, then add the microencapsulated probiotics and brewer's yeast powder, and stir at 50-100 rpm for 10-20 minutes until uniform. S4. Add 30%-50% ethanol aqueous solution as a wetting agent to the mixture in step S3, and prepare 100-200 mesh particles by wet granulation technology at 40-55℃. S5. Add 0.5%-2% of the total mass of the mitigating agent, flavoring agent, and 0.05%-0.2% of the natural antioxidant to the granules from step S4. After drying to a moisture content of 1%-3%, vacuum package them under a vacuum of 0.07 MPa-0.09 MPa to obtain the finished product.

[0010] Optionally, in step S2, microencapsulation is performed using spray drying, with an inlet air temperature of 160-180℃, an outlet air temperature of 70-90℃, and a microcapsule particle size of 5-20 μm.

[0011] Optionally, in step S4, after wet granulation, fluidized bed drying is performed at a temperature of 50-60℃ for 15-30 min, and the moisture content of the particles is controlled at 1%-2%.

[0012] Optionally, in step S5, the flavoring agent is selected from one or more of chicken powder, beef powder, fish powder, liver powder, pet-specific chicken flavor peptides, and pet-specific beef flavor peptides; the natural antioxidant is selected from one or more of vitamin E, tea polyphenols, rosemary extract, grape seed extract, and ascorbyl palmitate.

[0013] Optionally, the relieving agent is used in the preparation of products for the prevention or treatment of acute and chronic gastroenteritis in cats and dogs.

[0014] Optionally, the relief agent can be administered orally at a dose of 0.1-0.5 g per kg of body weight for cats and dogs, once or twice daily. It can be mixed into the diet or dissolved in warm water and administered orally. Continuous addition for 3-7 days during the stress period can prevent gastroenteritis.

[0015] The beneficial effects of this invention are: The cat and dog gastrointestinal inflammation relief agent prepared by this invention has an initial probiotic survival rate of 95%-99%, and the survival rate remains at 90%-95% after 2 hours in simulated gastrointestinal fluid, demonstrating outstanding stability against gastrointestinal fluid. The synergistic effect of plant extracts and probiotics can quickly relieve the symptoms of cat and dog gastroenteritis, regulate the balance of intestinal flora, and has no side effects. The sustained-release granules achieve targeted release in the intestine, effectively prolonging the period of action. Multiple natural flavoring agents enhance palatability, and high-purity plant extracts further enhance the product's functional effectiveness. Attached Figure Description

[0016] The accompanying drawings are provided to further illustrate the invention and form part of the specification. They are used together with the embodiments of the invention to explain the invention and do not constitute a limitation thereof.

[0017] Figure 1 This is a bar chart comparing the overall survival rate of gastrointestinal fluid in different samples according to the present invention. Figure 2This is a line graph comparing the gastric fluid release rate over 2 hours and the intestinal fluid release rate over 8 hours for different samples of this invention. Detailed Implementation

[0018] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention.

[0019] Example 1: This Example 1 describes a cat and dog gastrointestinal inflammation relief agent containing plant extracts, prepared from the following raw materials in parts by weight: The composition includes: 5 parts plant extract (1.5 parts licorice extract, 1.2 parts astragalus extract, 1.3 parts poria cocos extract, 1.0 part yam extract), 4 parts microecological components (1.0 part probiotics, 3.0 parts brewer's yeast powder), 7 parts functional auxiliary components (3.0 parts prebiotics, 4.0 parts montmorillonite powder), 5 parts composite encapsulation material (2.5 parts maltodextrin, 1.5 parts gum arabic, 1.0 part trehalose), 77.9 parts carrier raw materials (63 parts corn starch, 12 parts lactose, 2.9 parts sodium carboxymethyl cellulose), 1.0 part chicken powder flavoring agent, and 0.1 part vitamin E natural antioxidant. This embodiment describes a method for preparing a cat and dog gastrointestinal inflammation relief agent containing plant extracts. The specific preparation steps are as follows: S1. Mix the weighed plant extract components, pulverize them and pass them through an 80-mesh sieve. Add 10 times the mass of ethanol solution to the mixture. Set the ultrasonic power to 200 W, the extraction temperature to 50℃, and the total extraction time to 60 min. The ethanol gradient concentrations are 40% (30 min), 55% (20 min), and 70% (10 min) respectively. After extraction, filter and collect the filtrate. Concentrate it to a relative density of 1.2-1.3 at 55℃ and -0.08 MPa. Dilute it with deionized water to a solid content of 20%. Purify it through an ultrafiltration membrane with a molecular weight cutoff of 8000 Da. Collect the permeate and concentrate it again to a dry powder to obtain a plant extract component with a core active ingredient purity of 92%. S2. Maltodextrin, gum arabic, and trehalose were mixed at a mass ratio of 2.5:1.5:1.0, and dissolved in 10 times the volume of deionized water at 60°C by stirring to prepare a composite embedding material; Bifidobacterium and lactic acid bacteria were mixed and dissolved in sterile physiological saline at 4°C to prepare a solution with a concentration of 2×10⁻⁶. 9A probiotic suspension of CFU / mL was slowly added to the composite encapsulation material solution at a volume ratio of 1:5. The mixture was emulsified at 30℃ and 1000 rpm for 20 min, and then encapsulated using a spray drying method with an inlet air temperature of 170℃, an outlet air temperature of 80℃, a feed rate of 15 mL / min, and an atomization pressure of 0.3 MPa. The powdered microencapsulated probiotics were then collected. S3. Mix the plant extract components, functional auxiliary components, and carrier raw materials evenly, and dry them in a vacuum drying oven at 50°C until the moisture content is 3%. After cooling, add the microencapsulated probiotics and brewer's yeast powder, and stir at 80 rpm for 15 minutes until the materials are evenly dispersed. S4. Add 40% ethanol aqueous solution to the mixture as a wetting agent, and prepare granules by wet granulation technology at 50℃; after the wet granules are granulated through a 150-mesh sieve, they are dried by fluidized bed drying at a set drying temperature of 55℃ and a drying time of 20min, and the moisture content of the granules is controlled at 1.5% to obtain slow-release granules. Relying on the binding and slow-release characteristics of sodium carboxymethyl cellulose in the carrier raw material, the effective ingredients are slowly released. S5. Add 1% of the total mass of the slow-release agent, flavoring agent, and 0.1% of the natural antioxidant to the slow-release granules, mix evenly, and dry to a moisture content of 2%; pack the granules into aluminum foil composite bags and vacuum package them under a vacuum degree of 0.08 MPa to obtain the finished product.

[0020] Example 2: This Example 2 presents a cat and dog gastrointestinal inflammation relief agent containing plant extracts, prepared from the following raw materials in parts by weight: The composition includes: 3 parts plant extract (0.8 parts licorice extract, 0.6 parts astragalus extract, 0.8 parts poria cocos extract, 0.8 parts yam extract), 4 parts microecological components (1.0 part probiotics, 3.0 parts brewer's yeast powder), 7 parts functional auxiliary components (3.0 parts prebiotics, 4.0 parts montmorillonite powder), 5 parts composite encapsulation material (2.5 parts maltodextrin, 1.5 parts gum arabic, 1.0 part trehalose), 79.9 parts carrier raw materials (65 parts corn starch, 12 parts lactose, 2.9 parts sodium carboxymethyl cellulose), 1.0 part chicken powder flavoring agent, and 0.1 part vitamin E natural antioxidant. In this embodiment, the preparation method of a cat and dog gastrointestinal inflammation relief agent containing plant extracts is the same as that in Example 1, except that the plant extract component is reduced to 3 parts.

[0021] Example 3: This embodiment 3 presents a cat and dog gastrointestinal inflammation relief agent containing plant extracts, which is prepared from the following raw materials in parts by weight: The composition includes: 5 parts plant extract (1.5 parts licorice extract, 1.2 parts astragalus extract, 1.3 parts poria cocos extract, 1.0 part yam extract), 4 parts microecological components (1.0 part probiotics, 3.0 parts brewer's yeast powder), 7 parts functional auxiliary components (3.0 parts prebiotics, 4.0 parts montmorillonite powder), 5 parts composite encapsulation material (2.5 parts maltodextrin, 1.5 parts gum arabic, 1.0 part trehalose), 77.9 parts carrier raw materials (64.9 parts corn starch, 12 parts lactose, 1.0 part sodium carboxymethyl cellulose), 1.0 part chicken powder flavoring agent, and 0.1 part vitamin E natural antioxidant. In this embodiment, the preparation method of a cat and dog gastrointestinal inflammation relief agent containing plant extracts is the same as that in Example 1, except that the amount of sodium carboxymethyl cellulose is changed to 1.0 part.

[0022] Comparative Example 1: The relief agent in Comparative Example 1 was prepared from the following raw materials in parts by weight: The product contains 4 parts of microecological components (1.0 part of probiotics and 3.0 part of brewer's yeast powder), 7 parts of functional auxiliary components (3.0 parts of prebiotics and 4.0 parts of montmorillonite powder), 5 parts of composite encapsulation material (2.5 parts of maltodextrin, 1.5 parts of gum arabic and 1.0 part of trehalose), 82.9 parts of carrier raw materials (68 parts of corn starch, 12 parts of lactose and 2.9 parts of sodium carboxymethyl cellulose), 1.0 part of flavoring agent (chicken powder), and 0.1 part of natural antioxidant (vitamin E). The preparation method of the remedial agent in this comparative example is the same as that in Example 1, except that no plant extracts are added.

[0023] Comparative Example 2: The relief agent in Comparative Example 2 was prepared from the following raw materials in parts by weight: The composition includes: 5 parts plant extract (1.5 parts licorice extract, 1.2 parts astragalus extract, 1.3 parts poria cocos extract, 1.0 part yam extract), 4 parts microecological components (1.0 part probiotics, 3.0 parts brewer's yeast powder), 7 parts functional auxiliary components (3.0 parts prebiotics, 4.0 parts montmorillonite powder), 5 parts composite encapsulation material (2.5 parts maltodextrin, 1.5 parts gum arabic, 1.0 part trehalose), 77.9 parts carrier raw materials (63 parts corn starch, 12 parts lactose, 2.9 parts sodium carboxymethyl cellulose), 1.0 part chicken powder flavoring agent, and 0.1 part vitamin E natural antioxidant. The preparation method of the resuscitator in this comparative example is the same as that in Example 1. The probiotics were not microencapsulated. Bifidobacteria and lactic acid bacteria were mixed and dissolved in 5 times their mass of sterile physiological saline at 4°C. The mixture was magnetically stirred for 10 min to prepare a probiotic suspension. The composite encapsulation material solution was directly mixed with the probiotic suspension and stirred at 30°C and 1000 rpm for 10 min.

[0024] Performance testing 1. Probiotic survival rate test in simulated gastrointestinal fluid Artificial gastric fluid (pH=1.2, containing 1% pepsin) and artificial intestinal fluid (pH=6.8, containing 1% trypsin) were prepared according to the "Technical Specifications for Inspection and Evaluation of Health Foods". 1.0 g of each of the relief agents from Examples 1-3 and Comparative Examples 1-2 were pulverized and added to 10 mL of sterile physiological saline. The mixture was magnetically stirred for 30 min to form a homogeneous suspension. 1 mL of the suspension was inoculated into 9 mL of artificial gastric fluid and incubated at 37°C and 100 rpm for 2 h with gentle shaking every 30 min. After incubation, 1 mL of the gastric fluid suspension was serially diluted with sterile physiological saline to a suitable concentration and plated using the MRS plate count method. The mixture was then anaerobically cultured at 37°C for 48 h, and the viable bacterial count was counted (denoted as N1). The remaining gastric fluid suspension was transferred into 9 mL of artificial intestinal fluid and incubated at 37°C and 100 rpm for another 8 h. h, the number of viable bacteria was counted by diluting and coating the sample using the same method (denoted as N2); another initial suspension was directly diluted and counted, denoted as N0. The survival rate of the simulated gastric fluid over 2 hours was calculated using the formula "Survival rate (%) = (N1 / N0) × 100%", and the survival rate of the simulated gastrointestinal fluid throughout the entire process was calculated using the formula "Cumulative survival rate (%) = (N2 / N0) × 100%". Three parallel experiments were set up for each sample, and the average value of the results was taken.

[0025] Table 1. Survival rate test data of probiotics in simulated gastrointestinal fluid for different samples. The survival rate of probiotics in gastric fluid in Examples 1-3 and Comparative Example 1 (all encapsulated in microcapsules) remained stable at 91%-93% for 2 hours, with an overall survival rate of about 85%, which meets the requirements of the claims. The survival rate of Comparative Example 2 (without encapsulation) dropped sharply, directly proving that microcapsulation technology is the key to protecting the activity of probiotics, and that plant extracts and sodium carboxymethyl cellulose do not affect the survival stability of probiotics.

[0026] 2. In vitro sustained-release characteristics test Following the dissolution determination method (paddle method) in the Chinese Pharmacopoeia, artificial gastric fluid (pH=1.2, containing 1% pepsin) and artificial intestinal fluid (pH=6.8, containing 1% trypsin) were prepared as release media. The dissolution apparatus was set to a speed of 50 rpm and a temperature of 37℃±0.5℃. 1.0 g (accurate to 0.001 g) of each of the sustained-release granule samples from Examples 1-3 and Comparative Examples 1-2 were placed in a dissolution vessel, and 500 mL of artificial gastric fluid was added as the initial release medium. The dissolution apparatus was started, and 5 mL samples were taken after 2 h of incubation (with an equal amount of preheated artificial gastric fluid at 37℃ added simultaneously to maintain a constant volume). After filtration through a 0.45 μm filter membrane, the content of glycyrrhizic acid (a representative component of the plant extract) in the filtrate was detected by high-performance liquid chromatography (HPLC), and the cumulative release in the gastric fluid over 2 h was calculated. After 2 h of sampling, 500 mL of artificial intestinal fluid was added to the dissolution vessel (making the total volume of the release medium 1000 mL, pH...). Adjust to 6.8), continue incubation for 8 h, sample and filter using the same method and detect glycyrrhizic acid content, calculate the cumulative release in intestinal fluid over 8 h, set up 3 parallel experiments for each sample, and take the average value of the results.

[0027] Table 2. Test data on the in vitro sustained-release characteristics of different samples Examples 1-2 showed the best sustained-release effect, with 24%-26% released from gastric juice after 2 hours and 77%-79% released from intestinal juice after 8 hours, fully meeting the scope defined in the claims. Example 3 (low-carboxymethyl cellulose sodium) showed a slightly reduced sustained-release effect but still met the requirements, verifying the rationality of the dosage range for this component. The release data of Comparative Examples 1-2 showed no significant difference from the examples, indicating that the sustained-release effect was determined solely by the carboxymethyl cellulose sodium.

[0028] 3. Animal experiments on the relief of gastrointestinal inflammation in vivo Sixty healthy SD rats (weighing 200-220 g, half male and half female) were randomly divided into a blank control group, a model control group, Example 1-3 groups, and Comparative Example 1-2 groups, with 10 rats in each group. After 3 days of acclimatization feeding, except for the blank control group, the other groups were given indomethacin (10 mg / kg) by gavage to establish an acute gastroenteritis model. The blank control group was given an equal volume of physiological saline by gavage. 24 h after modeling, Example 1-3 groups and Comparative Example 1-2 groups were given the corresponding relief agent (dissolved in physiological saline) at 0.3 g / kg body weight by gavage. The blank control group and the model control group were given an equal volume of physiological saline by gavage. The administration was once daily for 7 consecutive days. During the administration period, the food intake, diarrhea frequency, and mental status of the rats in each group were recorded daily. After the administration was completed, the rats were fasted for 12 days. h, blood was collected from the orbital cavity to separate serum. The levels of inflammatory factors (TNF-α, IL-6) and gastrointestinal protective factors (prostaglandin E2) in the serum were detected by enzyme-linked immunosorbent assay (ELISA). Subsequently, the rats were sacrificed, and the stomach and small intestine tissues were dissected to observe the external damage of the mucosa. Pathological sections were prepared, stained with hematoxylin and eosin (HE), and observed under an optical microscope to observe the degree of inflammatory cell infiltration, mucosal erosion, and villus damage. The pathological damage scoring scale (0-4 points, with higher scores indicating more severe damage) was used for quantitative assessment.

[0029] Table 3. Experimental data on the reduction of gastrointestinal inflammation in different samples in animal experiments. Animal experiments confirmed that after administration, rats in Examples 1-3 showed a significant recovery in food intake, a substantial reduction in diarrhea frequency, and a decrease of more than 60% in inflammatory factor content compared to the model control group. Their gastrointestinal mucosal damage scores were ≤1.2, indicating a significant alleviating effect. Comparative Example 1 (without plant extract) and Comparative Example 2 (without probiotic encapsulation) showed worse results than the Example groups, clarifying the synergistic anti-inflammatory effect of plant extracts and probiotics and the necessity of microcapsule encapsulation technology.

[0030] 4. Detection of active ingredient content in plant extracts Take 0.5 g (accurate to 0.0001 g) each of the purified plant extract powders from Examples 1-3 and Comparative Examples 1-2, and divide them into 3 portions for the detection of 3 types of components respectively. For glycyrrhizic acid detection, place the sample in a 50 mL centrifuge tube, add 25 mL of 70% ethanol, and extract ultrasonically for 30 min (power 200 W, temperature 50℃). After centrifugation (8000 rpm, 10 min), collect the supernatant, filter through a 0.45 μm filter membrane, and detect using high-performance liquid chromatography (HPLC). The chromatographic column is a C18 column (4.6 mm × 250 mm, 5 μm), the mobile phase is methanol-0.2% phosphoric acid solution (65:35, V / V), the detection wavelength is 254 nm, the flow rate is 1.0 mL / min, and the column temperature is 30℃. The glycyrrhizic acid content is calculated using the external standard method. For Astragalus polysaccharides and Poria polysaccharides detection, add 50 mL of distilled water to the sample and extract in a boiling water bath for 2 minutes. h, after filtration, take the filtrate, add 3 times the volume of anhydrous ethanol to precipitate the polysaccharides, centrifuge to collect the precipitate and dry it, use the phenol-sulfuric acid method for color development, use glucose as standard, measure the absorbance at a wavelength of 490 nm, and calculate the polysaccharide content through the standard curve; for the detection of various components of each sample, 3 sets of parallel experiments were set up, and the results were taken as the average value. The final detection results are expressed as "the percentage of the content of various components in the total mass of plant extract".

[0031] Table 4. Detection data of active ingredient content in plant extracts from different samples. The total content of the core active ingredients in the plant extracts of Examples 1-3 and Comparative Example 2 remained consistently above 31%, matching the process parameters, demonstrating the stability and effectiveness of the ultrasonic extraction-ultrafiltration purification process. There were no significant differences in component content under different formulation variables, indicating that component purity is only related to the extraction process, and that the content of active ingredients met the standards, providing component support for the synergistic anti-inflammatory effect.

[0032] 5. Palatability test of cat and dog gastrointestinal inflammation relief agent Twenty healthy adult domestic cats and twenty domestic dogs (cats weighing 2.5-3.5 kg and dogs weighing 8-12 kg, half male and half female) were selected and randomly divided into two groups of ten cats and ten dogs in each group. After three days of acclimatization, the control group was fed a basal diet, while the experimental group was fed a mixed diet consisting of a basal diet and a 1% symptom reliever. Equal amounts of feed were fed at fixed times each day, and the feed intake rate (number of animals eating / total number of animals) and feed intake (actual feed weight / feed weight × 100%) were recorded within one hour. The feeding was continued for seven days, and the feeding behavior of the pets (whether they actively ate and whether they refused to eat) was observed and recorded daily. Three parallel experiments were set up for each breed, and the average value of the results was taken.

[0033] Table 5. Palatability test data of different samples of cat and dog gastrointestinal inflammation relief agents The mixed feed with the mitigating agent from Example 1 had no negative impact on the feed intake rate and amount of domestic cats and dogs, and was basically the same as the basal diet control group. All pets in the experimental group actively ate the food and there was no refusal to eat, which proves that the product has good palatability and can ensure that pets can eat smoothly in actual use.

[0034] The above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit it. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A gastrointestinal inflammation reliever for cats and dogs containing plant extracts, characterized in that, The relieving agent is prepared from the following raw materials in parts by weight: The composition includes 3-8 parts plant extract, 2-6 parts microecological components, 4-10 parts functional auxiliary components, 3-8 parts composite encapsulation material, 0.5-2 parts flavoring agent, 0.05-0.2 parts natural antioxidant, and 65.8-87.45 parts carrier raw material. The plant extract components include 0.8-2 parts of licorice extract, 0.6-1.8 parts of astragalus extract, 0.5-1.5 parts of poria cocos extract, and 0.5-1.2 parts of yam extract; the microecological components include 0.5-1.5 parts of probiotics and 1-3 parts of brewer's yeast powder, wherein the probiotics contain 0.2-0.6 parts of bifidobacteria and 0.3-0.9 parts of lactic acid bacteria; the functional auxiliary components include 1.5-4 parts of prebiotics and 2-4 parts of montmorillonite powder, wherein the prebiotics contain 0.5-1.5 parts of xylooligosaccharides, 0.4-1.2 parts of fructooligosaccharides, and 0.3-0.8 parts of galactooligosaccharides; the composite encapsulation material includes 1-4 parts of maltodextrin, 0.5-3 parts of gum arabic, and 0.3-2 parts of trehalose; the carrier raw material includes 50-75 parts of corn starch, 5-12 parts of lactose, and 1-3 parts of sodium carboxymethyl cellulose.

2. The cat and dog gastrointestinal inflammation reliever containing plant extracts according to claim 1, characterized in that, The probiotics are microencapsulated compound probiotics, and the survival rate of the probiotics in the preparation is 90%-95% in simulated gastrointestinal fluid for 2 hours.

3. The cat and dog gastrointestinal inflammation reliever containing plant extracts according to claim 1, characterized in that, The reliever is a sustained-release granule with an in vitro release rate of 20%-30% in gastric juice after 2 hours and 70%-90% in intestinal juice after 8 hours.

4. The method for preparing a cat and dog gastrointestinal inflammation reliever containing plant extracts according to claim 1, characterized in that, The specific preparation steps are as follows: S1. Using ultrasound-assisted ethanol gradient elution combined with membrane separation purification technology, licorice, astragalus, poria cocos and yam were extracted and purified respectively. The extraction conditions were: ultrasonic power 150-300 W, extraction temperature 40-60℃, extraction time 30-90 min, ethanol gradient concentration 30%-80%, and ultrafiltration membrane with a molecular weight cutoff of 5000-10000 Da was used for membrane separation to obtain plant extracts with a core active ingredient purity of 85%-98%. S2. A composite encapsulation material is prepared by mixing maltodextrin, gum arabic, and trehalose in a mass ratio of 1-3:1-2:0.5-1. This material is used to microencapsulate Bifidobacteria and Lactobacillus to ensure a probiotic survival rate of 95%-99% in the formulation. S3. Mix the plant extract components, functional auxiliary components, and carrier raw materials evenly, dry them to a moisture content of 2%-5%, then add the microencapsulated probiotics and brewer's yeast powder, and stir at 50-100 rpm for 10-20 minutes until uniform. S4. Add 30%-50% ethanol aqueous solution as a wetting agent to the mixture in step S3, and prepare 100-200 mesh particles by wet granulation technology at 40-55℃. S5. Add 0.5%-2% of the total mass of the mitigating agent, flavoring agent, and 0.05%-0.2% of the natural antioxidant to the granules from step S4. After drying to a moisture content of 1%-3%, vacuum package them under a vacuum of 0.07 MPa-0.09 MPa to obtain the finished product.

5. The method for preparing a cat and dog gastrointestinal inflammation reliever containing plant extracts according to claim 4, characterized in that, In step S2, microencapsulation is performed using spray drying, with an inlet air temperature of 160-180℃, an outlet air temperature of 70-90℃, and a microcapsule particle size of 5-20 μm.

6. The method for preparing a cat and dog gastrointestinal inflammation reliever containing plant extracts according to claim 4, characterized in that, In step S4, after wet granulation, fluidized bed drying is performed at a temperature of 50-60℃ for 15-30 minutes, and the moisture content of the particles is controlled at 1%-2%.

7. The method for preparing a cat and dog gastrointestinal inflammation reliever containing plant extracts according to claim 4, characterized in that, In step S5, the flavoring agent is selected from one or more of chicken powder, beef powder, fish powder, liver powder, pet-specific chicken flavor peptides, and pet-specific beef flavor peptides; the natural antioxidant is selected from one or more of vitamin E, tea polyphenols, rosemary extract, grape seed extract, and ascorbyl palmitate.

8. A cat and dog gastrointestinal inflammation reliever containing plant extracts according to claim 1, characterized in that, The application of the reliever in the preparation of products for the prevention or treatment of acute and chronic gastroenteritis in cats and dogs.

9. The application of the plant extract-containing gastrointestinal inflammation reliever for cats and dogs according to claim 8, characterized in that, The relief agent is administered orally at a dose of 0.1-0.5 g per kg of cat or dog body weight, once or twice daily. It can be mixed into the diet or dissolved in warm water and administered orally. Continuous addition for 3-7 days during the stress period can prevent gastroenteritis.

Images